#AI reads Urine# Urine phospholipid profiling in patients with rheumatoid arthritis and nontuberculous mycobacterial pulmonary disease
Published 17 October, 2025
The study aimed to identify effective biomarkers for rheumatoid arthritis (RA) patients complicated with nontuberculous mycobacterial pulmonary disease (NTM-PD), as RA patients have a relatively high risk of developing NTM-PD, and existing biomarkers have insufficient sensitivity and may limit the treatment of RA. The study enrolled 90 RA patients (45 with NTM-PD and 45 without NTM-PD), matched the control group according to relevant criteria, and then conducted lipidomic analysis and various statistical analyses on their urine samples. The results showed that there were differences in the concentrations of some phospholipids in the urine between the two groups of patients. The partial least squares-discriminant analysis (PLS-DA) model constructed based on lysophosphatidic acid (LPA) 22:5 and phosphatidic acid (PA) 36:1 had higher sensitivity as a biomarker than the currently used anti-glycopeptidolipid core antibodies. The study had limitations such as a relatively small sample size and failure to cover differences in pathogenic species of NTM-PD in different regions. In the future, larger-scale and multi-population studies are needed to verify the results. Overall, this study is the first to identify phospholipid biomarkers with diagnostic potential for RA patients complicated with NTM-PD through urine lipidomic analysis, providing an effective method for the evaluation of related diseases.
Sci Rep. 2025 Oct 13;15(1):35694. doi: 10.1038/s41598-025-19452-2.
Youhe Gao
Statement: During the preparation of this work the author(s) used Doubao / AI reading for summarizing the content. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the published article.
For earlier AI Reads Urine articles：